3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
3
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
Specimen Handling
186
pembrolizumab
151
Magnetic Resonance Spectroscopy
151
Carboplatin
114
Biopsy
104
Cyclophosphamide
96
Cisplatin
88
Paclitaxel
79
Gemcitabine
71
Bevacizumab
68
fludarabine
60
Nivolumab
58
Fluorouracil
51
Radiotherapy
49
Dexamethasone
47
Capecitabine
47
Pemetrexed
46
Oxaliplatin
44
Docetaxel
44
Rituximab
43
Leucovorin
41
Doxorubicin
40
venetoclax
39
durvalumab
39
atezolizumab
39
Temozolomide
32
Standard of Care
32
Radiation
32
Cetuximab
32
130-nm albumin-bound paclitaxel
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Histamine Antagonists
×
30 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled